Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Repurposing Bi-Specific Chimeric Antigen Receptor (CAR) Approach to Enhance CAR T Cell Activity Against Low Antigen Density Tumors

Sherly Mardiana, PhD, Olga Shestova, PhD, Marco Ruella, MD, Saar Gill, MD PhD

Blood (2020) 136 (Supplement 1): 30.

https://doi.org/10.1182/blood-2020-140092

Published: 2020

Journal Articles

CRISPR-Cas9 Knock out of CD5 Enhances the Anti-Tumor Activity of Chimeric Antigen Receptor T Cells

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-136860

Published: 2020

Journal Articles

Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy

Blood (2019) 134 (Supplement_1): 247.

https://doi.org/10.1182/blood-2019-131024

Published: 2019

Journal Articles

CAR T Cell Cytotoxicity Is Dependent on Death Receptor-Driven Apoptosis

Nathan Singh, MD, Olga Shestova, PhD, Katharina Hayer, Albert Hong, Pranali Ravikumar, MS, Atushi Hoshino, MD PhD, Ophir Shalem, PhD, Matthew D. Weitzman, PhD, Carl H June, MD, Saar I. Gill, MDPhD, Marco Ruella, MD

Blood (2018) 132 (Supplement 1): 698.

https://doi.org/10.1182/blood-2018-99-117328

Published: 2018

Journal Articles

Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models

Marco Ruella, MD, Shannon L Maude, MD PhD, Boris Engels, PhD, David M. Barrett, Noelle Frey, MD, Katherine T Marcucci, PhD, Olga Shestova, PhD, Nathan Singh, MD, Jessica Perazzelli, PhD, David A Christian, PhD, Dana Haagen, BS, Simon F Lacey, PhD BS, J. Joseph Melenhorst, PhD, Jennifer Brogdon, PhD, Regina M Young, PhD, David L Porter, MD, Carl H June, MD, Stephan A Grupp, MD PhD, Saar I. Gill, MD PhD

Blood (2017) 130 (Supplement 1): 807.

https://doi.org/10.1182/blood.V130.Suppl_1.807.807

Published: 2017

Journal Articles

A Cellular Antidote to Specifically Deplete Anti-CD19 Chimeric Antigen Receptor (CAR19) Positive Cells

Marco Ruella, MD, David M. Barrett, Olga Shestova, PhD, Jessica Perazzelli, PhD, Avery D. Posey, PhD, Miroslaw Kozlowski, PhD, Simon F Lacey, PhD BS, J. Joseph Melenhorst, PhD, Carl H June, MD, Saar I. Gill, MD PhD

Blood (2017) 130 (Supplement 1): 4463.

https://doi.org/10.1182/blood.V130.Suppl_1.4463.4463

Published: 2017

Journal Articles

Engineering Resistance to Antigen-Specific Immunotherapy in Normal Hematopoietic Stem Cells By Gene Editing to Enable Targeting of Acute Myeloid Leukemia

Miriam Y Kim, MD, Saad S Kenderian, MD, Daniel Schreeder, MD PhD, Michael Klichinsky, PharmD, Miroslaw Kozlowski, PhD, Olga Shestova, PhD, Marco Ruella, MD, Saar I Gill, MBBS, PhD

Blood (2016) 128 (22): 1000.

https://doi.org/10.1182/blood.V128.22.1000.1000

Published: 2016

Journal Articles

Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor T Cells

Saad S Kenderian, MD, Marco Ruella, MD, Olga Shestova, PhD, Michael Klichinsky, PharmD, Miriam Y Kim, MD, Craig Soderquist, MD, Adam Bagg, MD, Reshma Singh, PhD, Celeste Richardson, PhD, Regina M Young, PhD, Carl H June, MD, Saar I. Gill, MD PhD

Blood (2016) 128 (22): 766.

https://doi.org/10.1182/blood.V128.22.766.766

Published: 2016

Journal Articles

Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model

Saad S Kenderian, MD, Marco Ruella, MD, Olga Shestova, PhD, Miriam Y Kim, MD, Michael Klichinsky, PharmD, Fang Chen, PhD, Natalka Kengle, Simon Francis Lacey, PhD BS, J. Joseph Melenhorst, PhD, Carl H June, MD, Saar I. Gill, MD PhD

Blood (2016) 128 (22): 652.

https://doi.org/10.1182/blood.V128.22.652.652

Published: 2016

Journal Articles

Kinase Inhibitor Ibrutinib Prevents Cytokine-Release Syndrome after Anti-CD19 Chimeric Antigen Receptor T Cells (CART) for B Cell Neoplasms

Marco Ruella, MD, Saad S Kenderian, MD, Olga Shestova, PhD, Michael Klichinsky, PharmD, J. Joseph Melenhorst, PhD, Mariusz A Wasik, MD, Simon F. Lacey, PhD, Carl H June, MD, Saar I Gill, MBBS, PhD

Blood (2016) 128 (22): 2159.

https://doi.org/10.1182/blood.V128.22.2159.2159

Published: 2016

Journal Articles

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells

Marco Ruella, MD, Michael Klichinsky, PharmD, Saad S Kenderian, MD, Olga Shestova, PhD, Amy Ziober, Michael D Feldman, MD, Mariusz A Wasik, MD, Carl H June, MD, Saar I Gill, MBBS, PhD

Blood (2016) 128 (22): 43.

https://doi.org/10.1182/blood.V128.22.43.43

Published: 2016

Journal Articles

Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia

Saad S Kenderian, MD, Marco Ruella, MD, Olga Shestova, PhD, Michael Klichinsky, PharmD, Miriam Y Kim, MD, David L Porter, MD, Carl H. June, MD, Saar I Gill, MBBS, PhD

Blood (2015) 126 (23): 852.

https://doi.org/10.1182/blood.V126.23.852.852

Published: 2015

Journal Articles

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Engraftment and Antitumor Responses Against Mantle Cell Lymphoma

Marco Ruella, MD, Saad S Kenderian, MD, Olga Shestova, PhD, Joseph A. Fraietta, PhD, Sohail Qayyum, MD, Qian Zhang, MD PhD, Marcela V. Maus, MDPhD, Xiaobin Liu, PhD, Selene Nunez-Cruz, PhD, Michael Klichinsky, PharmD, Omkar Uday Kawalekar, MS, BS, Michael C. Milone, MD PhD, Simon F. Lacey, PhD BSc, Anthony Mato, MD, Stephen J. Schuster, MD, Michael Kalos, PhD, Carl H. June, MD, Saar I Gill, MBBS, PhD, Mariusz A. Wasik, MD

Blood (2015) 126 (23): 704.

https://doi.org/10.1182/blood.V126.23.704.704

Published: 2015

Journal Articles

Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment and Prevention of Antigen-Loss Relapses Occurring after CD19-Targeted Immunotherapies

Marco Ruella, MD, David M. Barrett, MD PhD, Saad S Kenderian, MD, Olga Shestova, PhD, Ted J. Hofmann, PhD, John Scholler, Simon F. Lacey, PhD BSc, J. Joseph Melenhorst, PhD, Farzana Nazimuddin, Jessica Perazzelli, PhD, David A Christian, PhD, Christopher A Hunter, PhD, David L Porter, MD, Carl H. June, MD, Stephan A. Grupp, MD PhD, Saar I Gill, MBBS, PhD

Blood (2015) 126 (23): 2523.

https://doi.org/10.1182/blood.V126.23.2523.2523

Published: 2015

Journal Articles

Novel Chimeric Antigen Receptor T Cells for the Treatment of CD19-Negative Relapses Occurring after CD19-Targeted Immunotherapies

Marco Ruella, MD, David Barrett, MD PhD, Saad S. Kenderian, MD, Olga Shestova, PhD, Ted J. Hofmann, PhD, John Scholler, Simon F. Lacey, PhD BSc, Jan J Melenhorst, PhD, Farzana Nazimuddin, MS, Michael Kalos, PhD, David L. Porter, MD, Carl H. June, MD, Stephan A. Grupp, MD PhD, Saar I. Gill, MD PhD

Blood (2014) 124 (21): 966.

https://doi.org/10.1182/blood.V124.21.966.966

Published: 2014

Journal Articles

Novel Chimeric Antigen Receptor T Cells for the Treatment of Hodgkin Lymphoma

Marco Ruella, MD, Saad S Kenderian, MD, Olga Shestova, PhD, Taylor Chen, John Scholler, Mariusz A. Wasik, MD, Carl H. June, MD, Saar I. Gill, MD PhD

Blood (2014) 124 (21): 806.

https://doi.org/10.1182/blood.V124.21.806.806

Published: 2014

Journal Articles

Anti-CD123 Chimeric Antigen Receptor T Cells (CART-123) Provide A Novel Myeloablative Conditioning Regimen That Eradicates Human Acute Myeloid Leukemia In Preclinical Models

Saar Gill, MD, PhD, Sarah K Tasian, MD, Marco Ruella, MD, Olga Shestova, PhD, Yong Li, MD, MS, David L. Porter, MD, Martin Carroll, MD, Gwenn Danet-Desnoyers, PhD, John Scholler, Stephan A Grupp, MD, PhD, Carl H. June, MD, Michael Kalos, PhD

Blood (2013) 122 (21): 143.

https://doi.org/10.1182/blood.V122.21.143.143

Published: 2013

Journal Articles

Menin Regulates the Function of Lymphoid Progenitors and Hematopoietic Stem Cells.

Ivan Maillard, MD, PhD, Ya-Xiong Chen, PhD, Anthony T. Tubbs, Olga Shestova, PhD, Warren S. Pear, MD-PhD, Xianxin Hua, MD-PhD

Blood (2007) 110 (11): 1257.

https://doi.org/10.1182/blood.V110.11.1257.1257

Published: 2007

Journal Articles

Sporadic Notch1 Mutations Found in Human T-ALL Drive T Cell Development but Not Leukemogenesis in Murine Models: Implications for Pathogenesis and gamma-Secretase Inhibitor (GSI) Therapy.

Mark Y. Chiang, MD, PhD, Olga Shestova, PhD, Gavin Histin, PhD, Mina Xu, MD, Warren S. Pear, MD,PhD, Jon C. Aster, MD,PhD

Blood (2006) 108 (11): 707.

https://doi.org/10.1182/blood.V108.11.707.707

Published: 2006

Journal Articles

Canonical Notch Signaling Is Dispensable for the Maintenance of Adult Hematopoietic Stem Cells.

Ivan Maillard, MD, PhD, Seth E. Pross, Olga Shestova, PhD, Hong Sai, MD, Jon C. Aster, MD-PhD, Avinash Bhandoola, MD-PhD, Warren S. Pear, MD-PhD

Blood (2005) 106 (11): 267.

https://doi.org/10.1182/blood.V106.11.267.267

Published: 2005

NARROW

Repurposing Bi-Specific Chimeric Antigen Receptor (CAR) Approach to Enhance CAR T Cell Activity Against Low Antigen Density Tumors

CRISPR-Cas9 Knock out of CD5 Enhances the Anti-Tumor Activity of Chimeric Antigen Receptor T Cells

Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy

CAR T Cell Cytotoxicity Is Dependent on Death Receptor-Driven Apoptosis

Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models

A Cellular Antidote to Specifically Deplete Anti-CD19 Chimeric Antigen Receptor (CAR19) Positive Cells

Engineering Resistance to Antigen-Specific Immunotherapy in Normal Hematopoietic Stem Cells By Gene Editing to Enable Targeting of Acute Myeloid Leukemia

Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor T Cells

Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model

Kinase Inhibitor Ibrutinib Prevents Cytokine-Release Syndrome after Anti-CD19 Chimeric Antigen Receptor T Cells (CART) for B Cell Neoplasms

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells

Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Engraftment and Antitumor Responses Against Mantle Cell Lymphoma

Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment and Prevention of Antigen-Loss Relapses Occurring after CD19-Targeted Immunotherapies

Novel Chimeric Antigen Receptor T Cells for the Treatment of CD19-Negative Relapses Occurring after CD19-Targeted Immunotherapies

Novel Chimeric Antigen Receptor T Cells for the Treatment of Hodgkin Lymphoma

Anti-CD123 Chimeric Antigen Receptor T Cells (CART-123) Provide A Novel Myeloablative Conditioning Regimen That Eradicates Human Acute Myeloid Leukemia In Preclinical Models

Menin Regulates the Function of Lymphoid Progenitors and Hematopoietic Stem Cells.

Sporadic Notch1 Mutations Found in Human T-ALL Drive T Cell Development but Not Leukemogenesis in Murine Models: Implications for Pathogenesis and gamma-Secretase Inhibitor (GSI) Therapy.

Canonical Notch Signaling Is Dispensable for the Maintenance of Adult Hematopoietic Stem Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only